Chabiotech (085660) Fundamentals 2026 — Revenue Analysis | SniperIQ
Chabiotech (085660) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩644.4B, trading at ₩8550.00 on the KOE. This SniperIQ fundamentals page covers Chabiotech's valuation, profitability (net margin -5.7%), revenue (₩1.27T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Chabiotech's market cap?
Chabiotech (085660) has a market capitalization of approximately ₩644.4B, trading at ₩8550.00 on the KOE. Market cap moves with the live share price.
What is Chabiotech's P/E ratio?
Chabiotech's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Chabiotech?
Chabiotech runs a net profit margin of -5.7%, a gross margin of 26.9%, and an operating margin of -5.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Chabiotech generate?
Chabiotech reported revenue of ₩1.27T for fiscal year 2025, with net income of -₩109.9B and earnings per share (EPS) of -1636.98. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Chabiotech pay a dividend?
Chabiotech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Chabiotech financially healthy?
Chabiotech carries a debt-to-equity ratio of 1.85x and a current ratio of 0.88x, with a market beta of 0.57. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Chabiotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Chabiotech (085660) the key facts are: market cap ₩644.4B, revenue ₩1.27T, 52-week range 8420-23950. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Chabiotech's full fundamentals live
Get Chabiotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.